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Introduction
At the EPA Workshop on the SENCAR Mouse in
Toxicological Testing, held in Cincinnati, Ohio, on May
1 and 2, 1985, a general discussion was held on the
afternoon of the second day. All participants were in-
vited to attend. The discussion was chaired by Richard
J. Bull, Washington State University, Pullman, Wash-
ington. The focus ofdiscussion was the need for further
research. Participants were also encouraged to clarify
any questions and raise any issues concerning the pa-
pers presented during the previous 11/2 days.
The discussion fell into six general subject areas: ap-
plications of the SENCAR model, regression and pro-
gression ofpapillomas, comparative pathology of SEN-
CAR mice, basis for the increased sensitivity of the
SENCAR, use of SENCAR data in regulatory activi-
ties, and statistical evaluation of skin tumor data. This
paper summarizes the discussion and organizes the re-
marks into these six areas.
Applications of the SENCAR Model
Dr. R. Bull (Washington State University) com-
mented thatthere was aprobleminusingthe SENCAR
mouse assay across the board as a screening technique
because test results indicate that its use is restricted to
certain classes ofcompounds that impact certain target
organs. Given that restriction, he said, one should use
the SENCAR system as part of a battery of assays for
screening. He then asked Dr. S. Nesnow (EPA Carcin-
ogenesis and Metabolism Branch) to discuss the EPA's
research into using SENCAR data forrisk assessment.
Dr. Nesnowexplained that, three years ago, the EPA
was actively investigating the potential health hazards
of diesel exhaust because of pressure to dieselize the
automobile fleet. Since previous studies had shown that
these complex mixtures, particularlygasolineand diesel
exhausts, were weak carcinogens and would not induce
respiratory tumors in a variety of species, EPA re-
searchers had to utilize some alternate method for eval-
uating the comparative tumorigenic activity of these
complexmixtures. TheSENCAR mouseskinmodel was
chosen because it had historically been a very good and
sensitive systemforpolycyclics and someotherchemical
classes. In particular, it seemed to provide good dose-
response dataforcomplexmixtures. Usingthis system,
he continued, EPA researchers found that they could
obtain good reproducible dose-response data on tumor
incidence that could be quantitatively compared with
datafromothershort-termtestsystems(e.g., theAmes
test, mouse lymphoma gene mutation assay, cell trans-
formation assays) and with the human epidemiology.
This comparative potency technique showed a direct
relationship between mouse skin tumor initiating activ-
ity and human epidemiology (lung cancer) ofcoke oven
emissions, roofing tar emissions, and cigarette smoke.
There was an approximately 1,000-fold range of re-
sponse ofthese complex mixtures in humans and about
an 800-fold range ofresponse in mouse skin. Currently,
Dr. Nesnow said, EPA is continuing this line ofinves-
tigation by testing mixtures of more current interest,
such as wood smoke, as well as evaluating additional
reference carcinogens for which both mouse skin data
and human epidemiology data have been obtained.
In response, Dr. Bull said that he felt there were
definite limitations in how broadly this approach could
be applied to complex mixtures since there seems to be
a fairly high false-negative rate for compounds that
would ordinarily impact other target organs. For ex-
ample, based on his results with aromatic amines, he
would be very hesitant to use the SENCAR mouse to
judge the hazards of a dye effluent.
Dr. Nesnow agreed with this comment. Specifically
he said that researchers must at least know the broad
chemical classes of the major components of the mix-
ture, e.g., whethertheyarepolycycics orwhetherthey
are aromatic amines. For example, EPA research has
shown that several aromatic amines including a-na-
phthylamine and 4-aminobiphenyl were totally inactive
on mouse skin. Thus, it is essential, he said, that re-
searchers know what class of chemical they are evalu-
ating in order to select the most appropriate test sys-
tem, be itmouse skin, Ames, mouselymphoma, orsome
other system.
Dr. J. Strickland (National Cancer Institute) com-
mented that the SENCAR mouse was derived to be
sensitive to skin carcinogenesis by a certain protocol.
He said that, based on his knowledge of the literature
and the presentations at the workshop, there did not
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tivity of the SENCAR mouse in any other organ than
the skin. He felt that it was important that people in-
terested in using the mouse as a test system recognize
this fact.
Regression and Progression of
Papillomas
Dr. Bull then moved the discussion onto the subject
of regression and progression, particularly the pro-
gression to the malignant stage, a subject he felt to be
central to the use ofthe SENCAR mouse in short-term
screening. To open this discussion, he posed the follow-
ing question to Dr. H. Hennings [National Cancer In-
stitute (NCI)]: "Your results would suggest that there
are atleast two hitsinvolved incomplete carcinogenesis
and perhaps more. In addition, data you presented at
this workshop suggest a possible weakness in the use
of a gross papilloma count. These data showed that a
longer duration ofTPA treatment resulted in a greater
proportion of papillomas that then seemed to regress,
while a shorter duration of TPA treatment gave a pla-
teau of four or five papillomas per animal but these
papillomas seemed to progress more readily to carci-
nomas. Thus it appears that some papillomas progress
preferentially to carcinomas. From the vantage point
of the National Cancer Institute, how should this in-
formation influence the postures ofregulatory agencies
with respect to risk assessment models?"
Dr. HenningsagreedthatTPA-dependentpapillomas
are veryheterogeneous withrespect toprogression and
that many papillomas do not progress to carcinomas. In
lightofthisfact, hethoughtthatpapillomacountswould
not be a good basis for making regulatory decisions.
Instead he thought it would be better to base such de-
cisions on real carcinogenesis, i.e., the production of
carcinomas.
Supporting this point, Dr. Bull reminded the partic-
ipants ofa slide he had presented that showed the ratio
of papillomas to carcinomas. The shape of that curve
indicated thatrelativelylowpapillomayields hadhigher
conversion rates than higher yields.
Dr. Hennings responded. He reminded participants
that there is a limit to how many carcinomas an animal
can get before it dies. So, for example, if a mouse has
20 or 30 papillomas, it is not going to get more than 4
or 5 carcinomas. For this reason, mice with a high pap-
illoma incidence will never have a very high conversion
rate.
For that reason, Dr. Bull said, his data were limited
to groups with 10 or fewer papillomas. However, even
in the area of 1 to 3 papillomas, the rate of conversion
certainly changed as the papilloma yield increased.
Dr. B. Diwan (NCI Frederick Cancer Research Fa-
cility) asked Dr. Hennings what he thought the differ-
ences in biochemical reactions (DNA binding, etc.) of
normal epithelial cells and initiated cells to NQO or an
irritant in culture would be. Dr. Hennings replied that
he would like to develop a malignant conversion assay
in cell culture, but that he had not done that yet.
Dr. Nesnow said he thought there were some data in
the literature which suggestedthatboth DMBAand BP
gave parallel dose-response curves in the tumor initi-
ationprotocolwhenthe micewere scoredforpapillomas
at 6 months oftreatment or scored for carcinomas after
a year oftreatment with TPA. This suggested that the
papillomaresponse in thetumorinitiationprotocol (i.e.,
the number of papillomas per mouse) could be used to
indicate the carcinoma response in the tumor initiation
protocol (i.e., the number of mice bearing carcinomas)
for certain chemicals.
Dr. Bull indicated that a major reason for exploring
this issue was the need to find an economically feasible
system for screening potential carcinogens. He thought
that use ofa papilloma count was almost essential ifthe
SENCAR system was to be economically feasible for
screening.
Comparative Pathology of SENCAR
Mice
Dr. G. Knutsen (Pathology Associates, Inc.) then
posedthe question: Doesthepathologyofthe SENCAR
mouse vary dependingon the source ofthe mouse (e.g.,
Harlan, Oak Ridge) and if so, how does it vary?
Dr. A. Klein-Szanto (University of Texas System)
replied that Harlan animals did seem to be more sen-
sitive than the original Oak Ridge and the actual Fred-
erick animals. He said that in recent experiments atthe
University ofTexas, Harlan animals had shown a much
higher incidence of papillomas and carcinomas and a
shorter latency period than the original Oak Ridge an-
imals. Response in the Oak Ridge animals was similar
to response in Frederick colony animals. Also, he said,
Harlan animals are larger than the Oak Ridge animals.
Dr. W. Baird (Purdue University) said he thought
thatcontinualselectionwasessentialwithboththe Har-
lan and Oak Ridge stocks to avoid genetic drift that
would result in increased variability and decreased sen-
sitivity. For example, he continued, Boutwell (1) re-
cently compared a strain that he had maintained and
continually selected with one of the commercial SEN-
CAR strains. He found a small but distinct difference
in sensitivity. Accordingto Dr. Baird, this wasjust one
example ofthe need to conduct DMBA and TPA selec-
tion periodically-for example every 1 or 2 years.
Dr. Knutsen said he had seen some differences in the
kidneylesions ofHarlan and OakRidgemice, and asked
whether other participants had observed a difference.
Dr. Klein-Szanto commented that his studies had
shown a very low incidence of amyloid in the kidneys
ofTPA-treated, 2-year-old Oak Ridge animals, but that
approximately 60 percent ofthe animals had amyloid in
the liver or spleen.
Dr. J. Ward (National Cancer Institute) said he had
seentwo cases ofliverandspleenamyloid andintestinal
amyloid in 2 of 30 Harlan mice treated with TPA for 2
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years. Aside from that, he said, amyloid in the liver,
spleen, and gut was extremely rare in his animals.
Dr. Claudio J. Conti (University of Texas Cancer
Center) reported that about 10 percent of approxi-
mately 400 untreated SENCAR mice had amyloid in
the liver or spleen.
Basis for the Increased Sensitivity
of the SENCAR Mouse
Dr. Ward said that the National Cancer Institute had
conducted a study with a phthalate using SENCAR and
CD-1 mice. First, the phthalate was applied in a con-
tinuous promotion two-stage system; then athree-stage
system was used with two stages ofpromotion by TPA
followed by the phthalate. This study was positive in
the SENCAR and negative after 40 weeks in the CD-
1. He asked if anyone at the workshop knew of similar
data in which either an initiator or promoter gave con-
sistently positive results in the SENCAR and negative
results in other mouse strains. If so, he asked, what
does this mean? Could it mean that the SENCAR was
abnormally sensitive and therefore the data were not
relevant to othermouse strains, much less tothe human
population?
Dr. Nesnow replied that he had presented several
examples of that type of comparative data in his talk
and that Dr. T. Slaga (University of Texas) had other
data. Dr. Slaga's data indicated that C57 black mice did
not respond to TPA as a promoter, while the SENCAR
mice did, but that the SENCAR and C57 black mice
seemed to be somewhat equivalent in response to some
other chemicals including benzo(a)pyrene as a complete
carcinogen. Dr. Nesnow said that these data indicate
that the SENCAR does seem to be highly sensitive to
some but not all polycyclics, particularly DMBA and,
to some extent, benzo(a)pyrene. With other chemicals,
such as MNNG, however, the SENCAR is not more
sensitive.
Dr. Bull reminded participants that the SENCAR
wasapparentlyselected tobe sensitive tobothinitiators
and promoters. He suggested that, due tothis bivariate
selection, there might be more than one reason why the
SENCAR exhibits increased sensitivity in initiation-
promotion experiments. He asked ifresearch should be
conducted to look for more subtle differences between
strains and whether that was even feasible.
In response, Dr. Baird said he thought it would be
better to maintain one inbred strain, as Dr. Slaga had
suggested, than to maintain separate stocks selected
for sensitivity to initiators or promoters. With several
different stocks, he feltthatitwouldbe difficult to avoid
cross-breeding or in-breeding, and that they would be
very costly to maintain.
Dr. Bull said he had heard discussion attheworkshop
of two possible bases for the sensitivity of the SEN-
CAR: the differentiation initiated by calcium or TPA,
and the metabolic differences that Bill Baird identified
with PAHs in his experiments (2). He asked if either
or both of those were sufficient to account for the dif-
ference in sensitivity, or whether there might be some
other factor(s).
Dr. Strickland responded. He said he thought that
the SENCAR's increased sensitivity was probably due
to more than one factor, one of which was certainly a
metabolic component. He cited a recent paper by
DiGiovanni (3) which reported that DBA/2 mice were
as sensitive as SENCAR micetoinitiation with MNNG,
a directly acting carcinogen, and promotion with TPA.
However, when DMBA was used as the initiator, the
SENCAR mice were more sensitive than DBA/2 mice.
Thus, in Dr. Strickland's opinion, based on this and
other data including his own, it seemed that the SEN-
CAR was better than other strains at activating car-
cinogens that were not presented in their active form,
whereas the SENCAR was no more sensitive to initi-
ation than other mouse strains if the carcinogen was
presented in its active form to the basal cells, which are
the target cells. However, in order to reach the basal
cells, which are at the bottom of the epidermis, the
carcinogen must pass through all the upper layers of
the epidermis. Thus there may be some practical prob-
lems in presenting the carcinogen to the basal cells in
in vivo experiments that may affect the apparent sen-
sitivity of a strain to a particular carcinogen. In addi-
tion, Dr. Strickland continued, initiated SENCAR cells
may have a different sensitivity to promoters than in-
itiated cells of other mouse strains, so there may be
qualitative differences in the type of initiated cell with
respect to promotion.
Dr. G. Carlson (Purdue University) agreed with Dr.
Strickland that there was no simple explanation for the
increased sensitivity ofthe SENCAR. He said that the
data that he had presented at the workshop and other
data that would soon be published showed that, while
distribution and binding are very similar in the
BALB/c and the SENCAR, the amount of material
bound to the skin and to DNA in the tissues varies
between the two species, with the BALB/c showing a
higher degree of binding. This type of measurement
indicates binding to a whole group of cells. Its signifi-
cance is difficult to interpret, however he said it does
not agree with the tumorigenicity data.
Dr. Baird said he thought further study of cell me-
tabolism of the various mouse species in response to
initiators and promoters was necessary to elucidate a
biological basis for any differences in sensitivity.
Dr. Conti then asked whether anyone had any data
concerning the immunology of SENCAR mice. In re-
sponse, Dr. Strickland said that his laboratory had
foundthenumberofepidermalLangerhanscellsinfresh
epidermal sheets of BALB/c and SENCAR mice to be
indistinguishable when examined by three different
techniques: ATPase staining, Ia antigen, and Fc recep-
tors. Also, invivo assays atNCI hadshownLangerhans
cells from adult BALB/c and SENCAR mice to be in-
distinguishable in terms ofallo-antigen presenting abil-
ity and contact hypersensitivity. In other studies at
NCI, Dr. Strickland continued, SENCAR skin and
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BALB/cskinweregraftedtonudemouserecipientsthat
were then treated with DMBA initiation and TPA pro-
motion. The SENCAR grafts retained their sensitivity,
while the BALB/c grafts retained their resistance, al-
though the sensitivity level of the SENCAR was
slightly lower in the graft than it was in the intact an-
imal. In summary, Dr. Strickland said, the immunolog-
ical and skin graft experiments conducted at NCI in-
dicate no immunological differences between BALB/c
and SENCAR.
Dr. Klein-Szanto commented that the immunological
parametersreportedbyDr. Strickland wereallcellular-
related. Hewonderedifanyonehadanydataonhumoral
immunological parameters, but there was no response
to this remark.
Use of SENCAR Data in Regulatory
Activities
Dr. R.W. Niemeier (National Institute for Occupa-
tional Safety and Health) said he had been using the
C3H/HeJ almost exclusively for assessingcomplex mix-
tures. He had just completed a study with CD-1 and
C3H mice using asphalt fumes and coal tar pitch that
showed asphalt fumes to be highly carcinogenic. He is
now investigating the effects ofvarious fractions ofas-
phalt fumes using the C3H/HeJ strain. In addition, he
is using the SENCAR strain for some fractions to con-
firm their increased sensitivity. The response in the
SENCAR strain will be compared to the response in
the C3H/HeJ strain.
Dr. Ward pointed out that the EPA used approxi-
mately 11,000 SENCAR mice inthepast2years-more
than any other institution. He asked what EPA's plans
were for future or ongoing studies with the SENCAR,
and whether they would continue to use the SENCAR
at such a high rate.
Dr. Nesnowagreed that EPAhas amajorinvestment
inthe SENCAR, particularly in the areaofairpollution
research. He said EPA would definitely continue to
evaluate the SENCAR for comparative assessment of
complex mixtures and for screening ofsome pure chem-
icals, however this continued effort would be smaller
that EPA's previous effort, which had involved about
40,000 mice. Dr. Nesnow said he thought the SENCAR
mousewascurrentlyveryvaluableasastandardscreen-
ingsystem, however, it seemed, from discussions atthe
workshop, that more work needed to be done in dosing,
pathology, and sensitivity. He said that other govern-
ment agencies, particularly the National Toxicology
Program(NTP), wereinterestedinsupportingresearch
with the SENCAR.
Dr. W. Eastin (National Institute of Environmental
Health Sciences) confirmed that the National Toxicol-
ogy Program was interested in using the SENCAR for
initiation-promotion studies. He expressed concern
about the general lack of published data on the SEN-
CAR strain; however, he said that it was apparent from
the workshop that more information is available, but
not yet published. He said the NTP had a very large
data base on the B6C3F1 mouse, which it routinely
used, and was currently comparing this mouse with the
Swiss CD-1 andthe SENCAR inaninitiation/promotion
study. Dr. Eastin asked the participants whatthey con-
sidered to be the most appropriate kinds of controls in
initiation/promotion studies using the SENCAR, given
that there may be a major difference in stocks from the
two major suppliers.
In response to this question, Dr. R. M. Kovatch (Pa-
thology Associates, Inc.) suggested that the NTP use
the same approach they had originally used for the
B6C3F1 mouse, i.e., room controls which were elimi-
nated from the experiments when they were no longer
felt to be necessary.
Dr. Bull said the EPA had always run nonpromoted
vehicle controls in its experiments. These controls had
received acetone and had been shaved. Although these
controls were not, strictly speaking, untreated, there
was much data on them that could indicate what back-
ground is.
Dr. Klein-Szanto said that, based on the proceedings
oftheworkshop, thepathologyofthetwooriginalstocks
(Oak Ridge and Frederick) was apparently well char-
acterized, whereas there was much less data on the
Harlan stock. He said he had dataon approximately 500
untreated Oak Ridge mice.
Dr. Knutsen said his work was exclusively with Har-
lan mice but he did not feel his data could provide any
type of baseline at this point.
Dr. Ward said he currently had data on 12-month-old
mice and would have data on 2-year-old mice in a few
weeks. However he recommended that each institute
individuallycharacterize theircontrolsundertheunique
environmental conditions (feed, caging, hair clipping,
etc.) of their facility. That data could then be used for
comparison purposes.
Statistical Evaluation of the Skin
Tumor Data
Dr. Baird then moved onto the subject of statistical
analysis. He asked what was needed to get a good sta-
tistical analysis of the data in the SENCAR assay.
Dr. J. Stober (EPA Health Effects Research Labo-
ratory) responded. As the first phase in the statistical
design evaluation, she recommended looking at the con-
trol data to determine the spontaneous rate. Second,
she recommended standardizing the criteria forjudging
whether or not there had been a response. It is essen-
tial, she said, that researchers present these criteria-
for example, how they determined whether a lesion is
apapillomaoracarcinoma, andwhetherscoringisbeing
done objectively by the gross lesion or microscopi-
cally-so that the SENCAR assay can be objectively
evaluated and, more importantly, so that results can be
compared across time or between researchers. Finally,
she said the number ofanimals used directly affects the
value ofthe results. In particular, studies where many
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animals would be lost due to the toxicity of the com-
pound would require a large number of animals to de-
termine marginal response.
Concluding Remarks
Dr. Bull closed the discussion by thanking Merrel
Robinson for organizing the symposium. He reminded
participants not to forget the advantages of the SEN-
CAR despite the number ofcritical comments made at
the symposium: that it is a healthy, hardy mouse that
compares favorably in lifespan to other stocks ofmice,
is sensitive to carcinogens, and relatively easy to work
with.
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